JP2022542884A5 - - Google Patents

Info

Publication number
JP2022542884A5
JP2022542884A5 JP2022504569A JP2022504569A JP2022542884A5 JP 2022542884 A5 JP2022542884 A5 JP 2022542884A5 JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022504569 A JP2022504569 A JP 2022504569A JP 2022542884 A5 JP2022542884 A5 JP 2022542884A5
Authority
JP
Japan
Prior art keywords
amino acid
acid position
pharmaceutical composition
fcrn antagonist
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043533 external-priority patent/WO2021016571A2/en
Publication of JP2022542884A publication Critical patent/JP2022542884A/ja
Publication of JP2022542884A5 publication Critical patent/JP2022542884A5/ja
Priority to JP2025051382A priority Critical patent/JP2025098167A/ja
Pending legal-status Critical Current

Links

JP2022504569A 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法 Pending JP2022542884A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025051382A JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878541P 2019-07-25 2019-07-25
US62/878,541 2019-07-25
PCT/US2020/043533 WO2021016571A2 (en) 2019-07-25 2020-07-24 Methods of treating antibody-mediated disorders with fcrn antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025051382A Division JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Publications (2)

Publication Number Publication Date
JP2022542884A JP2022542884A (ja) 2022-10-07
JP2022542884A5 true JP2022542884A5 (enExample) 2023-07-31

Family

ID=72087159

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504569A Pending JP2022542884A (ja) 2019-07-25 2020-07-24 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025051382A Pending JP2025098167A (ja) 2019-07-25 2025-03-26 Ｆｃｒｎアンタゴニストで抗体媒介性障害を処置する方法

Country Status (13)

Country Link
US (1) US20210024620A1 (enExample)
EP (1) EP4004039A2 (enExample)
JP (2) JP2022542884A (enExample)
KR (1) KR20220038432A (enExample)
CN (1) CN114466663B (enExample)
AU (1) AU2020315925A1 (enExample)
BR (1) BR112022001255A2 (enExample)
CA (1) CA3148764A1 (enExample)
CO (1) CO2022001164A2 (enExample)
IL (1) IL290101A (enExample)
MX (1) MX2022001038A (enExample)
TW (1) TW202120539A (enExample)
WO (1) WO2021016571A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
WO2025008537A1 (en) 2023-07-05 2025-01-09 Ablynx Nv Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025041077A1 (en) 2023-08-23 2025-02-27 Sanofi Ctla-4-based lysosomal degraders and uses thereof
TW202535925A (zh) 2023-10-25 2025-09-16 比利時商艾伯霖克斯公司 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途
WO2025144848A1 (en) * 2023-12-27 2025-07-03 Vetmab Biosciences, Inc. FcRn ANTAGONISTS FOR VETERINARY USE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2018012383A (es) * 2011-03-30 2023-03-07 Chugai Pharmaceutical Co Ltd Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno.
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
UA118029C2 (uk) * 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
KR20170015920A (ko) * 2014-06-12 2017-02-10 에프. 호프만-라 로슈 아게 ＦｃＲｎ 상호작용이 변화된 항체를 선별하는 방법
DK3215528T3 (da) * 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
EP3625251A1 (en) * 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
IL276286B2 (en) * 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life

Similar Documents

Publication Publication Date Title
JP2022542884A5 (enExample)
JP2025098167A5 (enExample)
US8323646B2 (en) Engineered anti-IL-13 antibodies, compositions, methods and uses
RU2732226C2 (ru) Конъюгаты антитело-финомер
JP7116736B2 (ja) 操作されたヘテロ二量体タンパク質
JP2024026255A5 (enExample)
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
TW200840821A (en) Methods of purifying anti A beta antibodies
JP2010532764A5 (enExample)
JP2021511830A5 (enExample)
JP2020520231A5 (enExample)
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
SG176754A1 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
JP2023502968A5 (enExample)
JP2014513953A5 (enExample)
MX2010011761A (es) Anticuerpos para el factor que estimula la colonia del granulocito-macrofago.
JP2019525728A5 (enExample)
CA3193273A1 (en) Methods and compositions to treat autoimmune diseases and cancer
JP2011518857A5 (enExample)
KR20200106056A (ko) 자가면역 질환 및 암을 치료하기 위한 항-cxcl13 항체
RU2019123112A (ru) Анти-il-5 антитела
JP2024504923A5 (enExample)
JP2025533393A (ja) 免疫調節剤のスクリーニングと調製方法
JP2025026957A (ja) ＩＬ－１β受容体シグナル伝達に干渉する剤
JP2022523047A5 (enExample)